RxDoctor Payments DataLook up a doctor →

Laurence Chu, MD

Otolaryngology · Austin, TXNPI 1902854680

Payments from drug & device makers

$37,444,989in general payments, 2019–2025

Across 3,432 payments — averaging $10,911 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Modernatx, Inc.$18.7M
  • Pfizer$14.1M
  • Novavax Inc$1.6M
  • Sanofi Pasteur Inc.$1.1M
  • Janssen Research & Development, LLC$783K
  • GSK$489K
  • plus $699K from 11 others
$10,921in research payments, 2019–2025

Across 11 payments — averaging $992.82 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$8K
  • Sanofi Pasteur Inc.$2K
  • Novavax Inc$1K

General payments by program year

19
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$37,444,989 in reported general payments places this provider in the 95th percentile of 729 otolaryngology providers in Texas.

See all otolaryngology providers in Texas

Medicare billing

Part B allowed, 2024
$24,910
Medicare patients
96
Services billed
206

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other otolaryngology in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →